Roche: Exit Equities, Enter Drugs
Executive SummaryIt's the end of an era for Roche. Long known for its black-box financial dealings, the Swiss group has shut down investment arm Roche Finance and declared a renewed focus on its Pharma and Diagnostics businesses. The bold bid for transparency hasn't come cheap, but it's timely. Transparency is all the rage, and for the first time in years, Roche has something in its pipeline to point to.
You may also be interested in...
Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.
ICER’s influence on drug pricing, and policy, is growing. Spotlighting the worst drug price rises is one recent example.
Acquisitions and licensing are core to pharma and big biotech growth as pipelines thin and assets lose patent protection. Looking back at significantly sized acquisitions over just five years reveals that half of 2014’s acquisitions can already be judged as outright failures or, at best, questionable. But some lessons can be learned from dud deals.